Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

Kurozumi S, Joseph C, Raafat S, Sonbul S, Kariri Y, Alsaeed S, Pigera M, Alsaleem M, Nolan CC, Johnston SJ, Aleskandarany MA, Ogden A, Fujii T, Shirabe K, Martin SG, Alshankyty I, Mongan NP, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Jul;176(1):63-73. doi: 10.1007/s10549-019-05216-w. Epub 2019 Apr 2.

PMID:
30941650
2.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX.

Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28.

PMID:
30816325
3.

The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.

El-Ansari R, Craze ML, Alfarsi L, Soria D, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 May;175(1):27-38. doi: 10.1007/s10549-018-05111-w. Epub 2019 Jan 22.

PMID:
30671766
4.

Expression of Lamin A/C in early-stage breast cancer and its prognostic value.

Alhudiri IM, Nolan CC, Ellis IO, Elzagheid A, Rakha EA, Green AR, Chapman CJ.

Breast Cancer Res Treat. 2019 Apr;174(3):661-668. doi: 10.1007/s10549-018-05092-w. Epub 2019 Jan 4.

PMID:
30610489
5.

Glutamate dehydrogenase (GLUD1) expression in breast cancer.

Craze ML, El-Ansari R, Aleskandarany MA, Cheng KW, Alfarsi L, Masisi B, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Feb;174(1):79-91. doi: 10.1007/s10549-018-5060-z. Epub 2018 Nov 23.

PMID:
30470977
6.

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.

Johnston SJ, Ahmad D, Aleskandarany MA, Kurozumi S, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA.

BMC Cancer. 2018 Oct 23;18(1):1027. doi: 10.1186/s12885-018-4924-2.

7.

Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.

Alfarsi LH, Elansari R, Toss MS, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Jan;173(1):93-102. doi: 10.1007/s10549-018-4978-5. Epub 2018 Oct 10.

PMID:
30306428
8.

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.

Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsaleem M, Alsaeed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, Shirabe K, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28.

PMID:
30056565
9.

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Sonbul SN, Aleskandarany MA, Kurozumi S, Joseph C, Toss MS, Diez-Rodriguez M, Nolan CC, Mukherjee A, Martin S, Caldas C, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Nov;31(11):1675-1682. doi: 10.1038/s41379-018-0092-9. Epub 2018 Jun 28.

PMID:
29955149
10.

Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.

Miligy IM, Gorringe KL, Toss MS, Al-Kawaz AA, Simpson P, Diez-Rodriguez M, Nolan CC, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Dec;31(12):1807-1815. doi: 10.1038/s41379-018-0086-7. Epub 2018 Jun 28.

PMID:
29955142
11.

Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.

Althobiti M, Aleskandarany MA, Joseph C, Toss M, Mongan N, Diez-Rodriguez M, Nolan CC, Ashankyty I, Ellis IO, Green AR, Rakha EA.

Histopathology. 2018 Dec;73(6):887-896. doi: 10.1111/his.13695. Epub 2018 Oct 9.

PMID:
29947077
12.

Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.

Kurozumi S, Joseph C, Sonbul S, Gorringe KL, Pigera M, Aleskandarany MA, Diez-Rodriguez M, Nolan CC, Fujii T, Shirabe K, Kuwano H, Storr S, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Aug;170(3):525-533. doi: 10.1007/s10549-018-4777-z. Epub 2018 Apr 9.

PMID:
29633055
13.

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.

Joseph C, Macnamara O, Craze M, Russell R, Provenzano E, Nolan CC, Diez-Rodriguez M, Sonbul SN, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Mukherjee A.

Br J Cancer. 2018 Apr;118(8):1142-1151. doi: 10.1038/s41416-018-0041-x. Epub 2018 Mar 28.

14.

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.

El Ansari R, Craze ML, Miligy I, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res. 2018 Mar 22;20(1):21. doi: 10.1186/s13058-018-0946-6.

15.

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.

El Ansari R, Craze ML, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Br J Cancer. 2018 Apr;118(8):1115-1122. doi: 10.1038/s41416-018-0038-5. Epub 2018 Mar 16.

16.

MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.

Craze ML, Cheung H, Jewa N, Coimbra NDM, Soria D, El-Ansari R, Aleskandarany MA, Wai Cheng K, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Br J Cancer. 2018 Jan;118(2):258-265. doi: 10.1038/bjc.2017.387. Epub 2017 Nov 23.

17.

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.

Muftah AA, Aleskandarany MA, Al-Kaabi MM, Sonbul SN, Diez-Rodriguez M, Nolan CC, Caldas C, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2017 Jul;164(2):341-348. doi: 10.1007/s10549-017-4270-0. Epub 2017 May 6.

18.

Phenotypic characterisation of breast cancer: the role of CDC42.

Chrysanthou E, Gorringe KL, Joseph C, Craze M, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA, Ellis IO, Mukherjee A.

Breast Cancer Res Treat. 2017 Jul;164(2):317-325. doi: 10.1007/s10549-017-4267-8. Epub 2017 Apr 27.

19.

Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.

Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, Mukherjee A, Chapman C, Ellis IO, Green AR, Rakha EA.

Histopathology. 2017 Aug;71(2):258-268. doi: 10.1111/his.13217. Epub 2017 May 26.

PMID:
28326600
20.

Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.

Agboola AO, Ebili HO, Iyawe VO, Banjo AA, Salami BA, Rakha EA, Nolan CC, Ellis IO, Green AR.

Pathol Res Pract. 2017 Jan;213(1):27-33. doi: 10.1016/j.prp.2016.10.005. Epub 2016 Oct 25.

PMID:
27914769
21.

Further evidence to support bimodality of oestrogen receptor expression in breast cancer.

Muftah AA, Aleskandarany M, Sonbul SN, Nolan CC, Diez Rodriguez M, Caldas C, Ellis IO, Green AR, Rakha EA.

Histopathology. 2017 Feb;70(3):456-465. doi: 10.1111/his.13089. Epub 2016 Nov 28.

PMID:
27648723
22.

Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.

Green AR, Soria D, Stephen J, Powe DG, Nolan CC, Kunkler I, Thomas J, Kerr GR, Jack W, Cameron D, Piper T, Ball GR, Garibaldi JM, Rakha EA, Bartlett JM, Ellis IO.

J Pathol Clin Res. 2016 Jan 15;2(1):32-40. doi: 10.1002/cjp2.32. eCollection 2016 Jan.

23.

Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 Aug;159(1):199. No abstract available.

PMID:
27447877
24.

Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer.

Aleskandarany MA, Green AR, Ashankyty I, Elmouna A, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2016 Jul;158(2):287-95. doi: 10.1007/s10549-016-3893-x. Epub 2016 Jul 5.

PMID:
27380874
25.

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 May;157(1):65-75. doi: 10.1007/s10549-016-3804-1. Epub 2016 Apr 26. Erratum in: Breast Cancer Res Treat. 2016 Aug;159(1):199.

26.

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2016 Apr 12;114(8):917-28. doi: 10.1038/bjc.2016.46. Epub 2016 Mar 8.

27.

The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.

Aleskandarany MA, Agarwal D, Negm OH, Ball G, Elmouna A, Ashankyty I, Nuglozeh E, Fazaludeen MF, Diez-Rodriguez M, Nolan CC, Tighe PJ, Green AR, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2016 Feb;156(1):9-20. doi: 10.1007/s10549-016-3709-z. Epub 2016 Feb 23.

PMID:
26907764
28.

Clinical utility of reverse phase protein array for molecular classification of breast cancer.

Negm OH, Muftah AA, Aleskandarany MA, Hamed MR, Ahmad DA, Nolan CC, Diez-Rodriguez M, Tighe PJ, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2016 Jan;155(1):25-35. doi: 10.1007/s10549-015-3654-2. Epub 2015 Dec 9.

PMID:
26661092
29.

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer.

Alshareeda AT, Negm OH, Green AR, Nolan CC, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2015 Jun 9;112(12):1929-37. doi: 10.1038/bjc.2015.165. Epub 2015 May 19.

30.

The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.

Jerjees DA, Negm OH, Alabdullah ML, Mirza S, Alkaabi M, Hameed MR, Abduljabbar R, Muftah A, Nolan CC, Green AR, Tighe PJ, Band V, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2015 Feb;150(1):91-103. doi: 10.1007/s10549-015-3308-4. Epub 2015 Feb 21.

PMID:
25701120
31.

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.

Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2015 Feb;150(1):81-90. doi: 10.1007/s10549-015-3306-6. Epub 2015 Feb 19.

32.

Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response.

Al-Kaabi MM, Alshareeda AT, Jerjees DA, Muftah AA, Green AR, Alsubhi NH, Nolan CC, Chan S, Cornford E, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2015 Mar 3;112(5):901-11. doi: 10.1038/bjc.2014.576. Epub 2015 Feb 17.

33.

Biological and clinical significance of PARP1 protein expression in breast cancer.

Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2015 Jan;149(2):353-62. doi: 10.1007/s10549-014-3230-1. Epub 2014 Dec 21.

34.

Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts.

Syed BM, Green AR, Nolan CC, Morgan DA, Ellis IO, Cheung KL.

PLoS One. 2014 Jul 7;9(7):e100573. doi: 10.1371/journal.pone.0100573. eCollection 2014.

35.

Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.

Aleskandarany MA, Negm OH, Green AR, Ahmed MA, Nolan CC, Tighe PJ, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2014 Jun;145(2):339-48. doi: 10.1007/s10549-014-2927-5. Epub 2014 Apr 26.

PMID:
24771047
36.

Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart.

Agboola AO, Banjo AA, Anunobi CC, Ayoade BA, Deji-Agboola AM, Musa AA, Abdel-Fatah T, Nolan CC, Rakha EA, Ellis IO, Green AR.

Malays J Pathol. 2014 Apr;36(1):3-17.

37.

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.

Green AR, Barros FF, Abdel-Fatah TM, Moseley P, Nolan CC, Durham AC, Rakha EA, Chan S, Ellis IO.

Breast Cancer Res Treat. 2014 May;145(1):33-44. doi: 10.1007/s10549-014-2925-7. Epub 2014 Apr 6.

38.

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.

Rakha EA, Soria D, Green AR, Lemetre C, Powe DG, Nolan CC, Garibaldi JM, Ball G, Ellis IO.

Br J Cancer. 2014 Apr 2;110(7):1688-97. doi: 10.1038/bjc.2014.120. Epub 2014 Mar 11.

39.

Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay.

Barros FF, Abdel-Fatah TM, Moseley P, Nolan CC, Durham AC, Rakha EA, Chan S, Ellis IO, Green AR.

Breast Cancer Res Treat. 2014 Apr;144(2):273-85. doi: 10.1007/s10549-014-2871-4. Epub 2014 Feb 21.

PMID:
24557338
40.

SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy.

Jung Y, Abdel-Fatah TM, Chan SY, Nolan CC, Green AR, Ellis IO, Li L, Huang B, Lu J, Xu B, Chen L, Ma RZ, Zhang M, Wang J, Wu Z, Zhu T, Perry JK, Lobie PE, Liu DX.

Cancer Res. 2013 Dec 1;73(23):6951-62. doi: 10.1158/0008-5472.CAN-13-0982.

41.

Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers.

Green AR, Powe DG, Rakha EA, Soria D, Lemetre C, Nolan CC, Barros FF, Macmillan RD, Garibaldi JM, Ball GR, Ellis IO.

Br J Cancer. 2013 Oct 1;109(7):1886-94. doi: 10.1038/bjc.2013.528. Epub 2013 Sep 5.

42.

A quantifier-based fuzzy classification system for breast cancer patients.

Soria D, Garibaldi JM, Green AR, Powe DG, Nolan CC, Lemetre C, Ball GR, Ellis IO.

Artif Intell Med. 2013 Jul;58(3):175-84. doi: 10.1016/j.artmed.2013.04.006. Epub 2013 Jun 18.

PMID:
23791088
43.

Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women.

Agboola AO, Banjo AA, Anunobi CC, Salami B, Agboola MD, Musa AA, Nolan CC, Rakha EA, Ellis IO, Green AR.

ISRN Oncol. 2013 Apr 11;2013:675051. doi: 10.1155/2013/675051. Print 2013.

44.

Too many statistical errors for meaningful interpretation. Response to letter to the editor.

Agboola AJ, Musa AA, Wanangwa N, Abdel-Fatah T, Nolan CC, Ayoade BA, Oyebadejo TY, Banjo AA, Deji-Agboola AM, Rakha EA, Green AR, Ellis IO.

Breast Cancer Res Treat. 2013 Apr;138(2):645-50. No abstract available.

PMID:
23646372
45.

Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.

Gan A, Green AR, Nolan CC, Martin S, Deen S.

Hum Pathol. 2013 Aug;44(8):1638-47. doi: 10.1016/j.humpath.2013.01.015. Epub 2013 Apr 8.

PMID:
23574784
46.

Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study.

Rakha EA, Teoh TK, Lee AH, Nolan CC, Ellis IO, Green AR.

Histopathology. 2013 Apr;62(5):695-701. doi: 10.1111/his.12066. Epub 2013 Jan 24.

PMID:
23347178
47.

The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients.

Khoshnaw SM, Rakha EA, Abdel-Fatah T, Nolan CC, Hodi Z, Macmillan RD, Ellis IO, Green AR.

Breast Cancer Res Treat. 2013 Jan;137(1):139-53. doi: 10.1007/s10549-012-2358-0. Epub 2012 Dec 6.

PMID:
23225145
48.

Lack of expression of the proteins GMPR2 and PPARα are associated with the basal phenotype and patient outcome in breast cancer.

Baker BG, Ball GR, Rakha EA, Nolan CC, Caldas C, Ellis IO, Green AR.

Breast Cancer Res Treat. 2013 Jan;137(1):127-37. doi: 10.1007/s10549-012-2302-3. Epub 2012 Dec 4.

PMID:
23208589
49.

TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.

Aleskandarany MA, Negm OH, Rakha EA, Ahmed MA, Nolan CC, Ball GR, Caldas C, Green AR, Tighe PJ, Ellis IO.

Breast Cancer Res Treat. 2012 Nov;136(2):419-27. doi: 10.1007/s10549-012-2249-4. Epub 2012 Oct 4.

PMID:
23053644
50.

Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women.

Agboola AJ, Musa AA, Wanangwa N, Abdel-Fatah T, Nolan CC, Ayoade BA, Oyebadejo TY, Banjo AA, Deji-Agboola AM, Rakha EA, Green AR, Ellis IO.

Breast Cancer Res Treat. 2012 Sep;135(2):555-69. doi: 10.1007/s10549-012-2173-7. Epub 2012 Jul 29.

PMID:
22842985

Supplemental Content

Loading ...
Support Center